Preoperative Inflammatory Control and Surgical Outcome of Vitrectomy in Intermediate Uveitis
Table 2
Comparison of demographic and preoperative data between the two groups classified according to complete control of intraocular inflammation before vitrectomy.
Complete control of inflammation before vitrectomy
Yes
No
value
Number (patients)
36
30
Age
47.50 ± 14.46
50.47 ± 11.79
0.371
Gender (male : female)
22 : 14
18 : 12
0.927†
Preoperative follow-up period (months)
37.43 ± 50.64
26.93 ± 23.33
0.315
Preoperative BCVA
0.73 ± 0.67
0.91 ± 0.61
0.287
The last preoperative uveitic attack before vitrectomy (months)
16.81 ± 24.25
4.08 ± 3.08
0.012
Operation indications
0.144†
Epiretinal membrane
15
11
Vitreous opacity
8
13
Tractional retinal detachment
10
2
Macular edema
2
3
Vitreous hemorrhage
1
1
Total
36
30
The average number of uveitic attacks in the preoperative period (per year)
1.18 ± 0.91
1.72 ± 0.79
0.033
The average number of local injections in the preoperative period (per year)
0.78 ± 0.99
0.82 ± 1.12
0.888
The grade of vitreous haze before surgery
0.00 ± 0.00
1.30 ± 0.65
<0.001
The average number of systemic medications before surgery
0.55 ± 0.94
1.07 ± 1.08
0.044
BCVA, best-corrected visual acuity (in logarithm of the minimal angle of resolution); value was calculated using an independent t-test or Pearson’s chi-square test†.
